Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Guru Sonpavde MD
Guru P. Sonpavde MD Advisory Board
Roger Stupp MD
Roger Stupp MD Advisory Board
See All Experts
Published in Oncology

Journal Scan / Research · August 12, 2022

Adding Umbralisib and Ublituximab to Ibrutinib in Patients With CLL

Clinical Cancer Research

 

 Save  Recommend
 Share

Additional Info

Clinical Cancer Research
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach
Clin. Cancer Res 2022 Jul 19;[EPub Ahead of Print], LE Roeker, TA Feldman, JD Soumerai,V Falco, G Panton, C Dorsey , AD Zelenetz, L Falchi, JH Park, DJ Straus, C Pena Velasquez, S Lebowitz, Y Fox, K Battiato, C Laudati, MC Thompson, E McCarthy, S Kdiry, R Martignetti, T Turpuseema, M Purdom, D Paskalis, HP Miskin, P Sportelli, LA Leslie, AR Mato

Further Reading

Most Read This Week

Recently Updated